Biotoxicity Assessment of Oxidized Carbon Nanotubes: Testing Standards, Methods, and Regulatory Comp

Biotoxicity assessment of oxidized carbon nanotubes (o-CNTs) is a critical safety evaluation process that determines the cytotoxic, genotoxic, hemocompatible, and inflammatory potential of these surface-functionalized nanomaterials before their use in biomedical, industrial, and consumer applications. This technical article outlines the sample types, testing items, internationally recognized methods (ISO, ASTM, OECD, GB standards), and regulatory considerations involved in evaluating the biological safety of oxidized carbon nanotubes in accredited third-party laboratories.

Technical Overview

Oxidized carbon nanotubes (o-CNTs) are carbon nanotubes whose surfaces have been modified through acid treatment, plasma oxidation, or other oxidative functionalization processes, introducing carboxyl (-COOH), hydroxyl (-OH), and carbonyl groups onto the tube walls and ends. This surface modification significantly improves dispersibility in aqueous and biological media, enhances compatibility with polymers and ceramics, and enables covalent attachment of drugs, proteins, and targeting ligands—making o-CNTs valuable in drug delivery systems, tissue engineering scaffolds, biosensors, electrode coatings, and high-performance composite materials.

However, surface oxidation also alters the toxicological profile of the nanotubes. Functionalization changes tube length distribution, surface charge, aggregation behavior, protein corona formation, cellular uptake pathways, and clearance kinetics. Evidence from published nanotoxicology studies indicates that oxidized CNTs may exhibit reduced or enhanced toxicity relative to pristine CNTs depending on dose, length, residual catalyst metals, and test system. Consequently, manufacturers, biomedical developers, and regulatory bodies require systematic biotoxicity assessment to demonstrate product safety, support regulatory submissions, and manage occupational and environmental exposure risks.

A scientifically defensible biotoxicity assessment program for oxidized CNTs integrates physicochemical characterization with a tiered battery of in vitro and in vivo assays, conducted in accordance with international standards such as the ISO 10993 series for medical devices, ISO 19007 for nanotube-specific cytotoxicity testing, OECD test guidelines for chemical safety, and ASTM E2524/E2525/E2526 for nanomaterial hemocompatibility and cytotoxicity.

Testing Samples

Oxidized Single-Wall Carbon Nanotubes (SWCNT-COOH)

Carboxylated single-wall carbon nanotubes supplied as dry powder or aqueous dispersion. Typical submissions include specifications for purity (>90%), outer diameter (0.8–2 nm), length (0.5–30 μm), carboxyl group content (1.5–4.0 wt%), and residual metal catalyst content. These samples are evaluated for cytotoxicity, genotoxicity, and hemocompatibility across relevant dose ranges.

Oxidized Multi-Wall Carbon Nanotubes (MWCNT-COOH / MWCNT-OH)

Hydroxylated or carboxylated multi-wall carbon nanotubes in powder, paste, or dispersion form. Because MWCNTs dominate industrial composite and conductive additive applications, these samples are frequently assessed for occupational inhalation hazards, dermal irritation, and acute oral toxicity in addition to in vitro endpoints.

CNT-Containing Dispersions, Hydrogels, and Inks

Formulated products such as conductive inks, aqueous dispersions with surfactants or biopolymers, and injectable hydrogels. Extraction-based evaluation is performed to quantify the biological effects of releasable nanotube fractions and soluble components, following ISO 10993-12 sample preparation and extraction procedures adapted for nanomaterials.

Composite Materials and Medical Device Extracts

Finished articles incorporating oxidized CNTs—including catheter coatings, neural electrodes, orthopedic implant composites, wound dressings, and 3D-printed scaffolds. Extracts are generated under exaggerated and intended-use conditions to evaluate leachable-related toxicity per ISO 10993-5 and ISO/TR 10993-22 nanomaterial guidance.

Environmental and Ecotoxicology Test Samples

Stock suspensions prepared under standardized dispersion protocols for aquatic and terrestrial organism testing, supporting environmental risk assessment under chemical registration frameworks such as REACH.

Testing Items

Comprehensive biotoxicity evaluation of oxidized carbon nanotubes typically encompasses the following test categories:

• Physicochemical characterization for toxicological relevance: morphology and length distribution (TEM/SEM), surface chemistry (XPS, FTIR, Boehm titration), zeta potential, hydrodynamic size (DLS), specific surface area (BET), dispersion stability, and residual metal impurities (ICP-MS).
• In vitro cytotoxicity: cell viability and proliferation assays (MTT, CCK-8/WST-1, Alamar Blue), performed with nanomaterial interference controls per ISO 19007 and ISO 10993-5.
• Cell membrane damage: LDH release assay and neutral red uptake assessment.
• Oxidative stress markers: intracellular reactive oxygen species (ROS/DCF), glutathione (GSH) depletion, superoxide dismutase (SOD) activity, malondialdehyde (MDA) quantification, and 8-OHdG DNA oxidation biomarkers.
• Genotoxicity: bacterial reverse mutation assay (Ames, OECD TG 471), in vitro micronucleus test (OECD TG 487), comet assay (OECD TG 489), and chromosome aberration testing per ISO 10993-3.
• Hemocompatibility: hemolysis ratio, complement activation (SC5b-9, C3a), platelet aggregation, coagulation profiling (PT, APTT, thrombin generation), and thrombogenicity assessment per ISO 10993-4 and ASTM E2524.
• Inflammation and immunotoxicity: cytokine release profiling (TNF-α, IL-6, IL-1β, IL-8 by ELISA), macrophage phagocytic capacity, phagolysosome escape evaluation, pyrogen/endotoxin testing (LAL assay per ISO 29701), and immune cell activation studies.
• Acute systemic toxicity: acute oral toxicity (OECD TG 423/425), acute dermal toxicity, and acute inhalation toxicity (OECD TG 403) for powder-handling scenarios.
• Irritation and sensitization: skin irritation, eye irritation, intracutaneous reactivity, and sensitization testing including the local lymph node assay (OECD TG 429).
• Sub-acute and sub-chronic toxicity: repeated-dose 28-day and 90-day studies with histopathology, biodistribution, and clearance analysis.
• Eco-toxicity: Daphnia magna immobilization, zebrafish embryo toxicity (FET), algal growth inhibition, earthworm reproduction, and microbial community effects for environmental hazard classification.

Testing Methods

Accredited third-party laboratories apply a standards-based testing workflow designed to address the unique analytical challenges posed by carbon nanotubes, including optical assay interference, adsorption of assay reagents, and dispersion variability:

Sample Preparation and Dispersion Characterization

Test suspensions are prepared using standardized protocols (e.g., sonication in protein-containing media) followed by verification of hydrodynamic diameter, polydispersity index, and zeta potential by dynamic light scattering. Endotoxin contamination is screened using the kinetic chromogenic LAL method per ISO 29701 to distinguish true inflammatory responses from endotoxin-driven artifacts.

MTT Cytotoxicity Testing with Interference Control

ISO 19007 specifies an MTT-based method developed specifically for carbon nanotube samples, incorporating controls for formazan crystal adsorption and absorbance interference. Parallel cell viability assays using orthogonal readouts (e.g., Alamar Blue fluorescence with quenching controls, ATP luminescence, clonogenic survival) are employed to confirm results, consistent with ISO 10993-5 acceptance criteria (typically <70% viability indicating cytotoxic potential).

Cell Line Selection and Exposure Design

Assays are conducted with exposure-route-relevant cell models, commonly including L929 fibroblasts (ISO 10993-5 reference cells), A549 and BEAS-2B lung epithelial cells for inhalation-relevant exposure, Caco-2 intestinal cells for oral exposure, HaCaT keratinocytes for dermal contact, HUVEC endothelial cells for blood-contacting applications, and THP-1 macrophages for inflammatory profiling. Dose ranges typically span 0.01–200 μg/mL with 24, 48, and 72-hour exposure intervals.

Genotoxicity and Hemocompatibility Protocols

Genotoxicity batteries follow ISO 10993-3 and OECD guidelines, with micronucleus scoring by flow cytometry or microscopy and comet assay visualization under alkaline conditions. Hemocompatibility testing follows ISO 10993-4 and ASTM E2524, reporting hemolysis percentages against ASTM acceptance thresholds and evaluating complement and coagulation cascades using human donor blood.

In Vivo Studies

Animal studies are performed under GLP-compliant conditions in certified facilities with ethical committee approval, following OECD test guidelines and ISO 10993-11 for systemic toxicity. Biodistribution and persistence are tracked using Raman spectroscopy, electron microscopy of tissues, and stable isotope labeling, with particular attention to pulmonary retention and translocation to secondary organs following inhalation exposure per ISO 10808.

Data Reporting and Risk Characterization

Final reports present dose–response relationships, benchmark concentration (BMC) analysis, no-observed-adverse-effect levels (NOAEL), and hazard classification conclusions aligned with the Globally Harmonized System (GHS), supporting downstream risk assessment and regulatory dossiers.

Applications

• Biomedical product development: safety substantiation for o-CNT-based drug delivery carriers, photothermal therapy agents, imaging probes, and implantable electrode coatings prior to preclinical studies.
• Medical device regulatory registration: biological evaluation documentation for regulatory submissions under frameworks requiring ISO 10993 compliance, including nanomaterial-specific considerations from ISO/TR 10993-22.
• Chemical substance notification: hazard data packages for new nanomaterial registrations under REACH in the EU, the US EPA TSCA program, and new chemical substance registration schemes in China and other jurisdictions.
• Occupational health and safety: exposure characterization and hazard identification for workplaces manufacturing or processing oxidized CNT powders, supporting engineering control decisions and worker protection programs.
• Environmental risk assessment: ecotoxicity data for lifecycle analysis, waste stream evaluation, and environmental release modeling of CNT-enabled products.
• Research and quality control: batch-to-batch biological safety screening for CNT manufacturers and comparative assessment of functionalization strategies to guide safer-by-design material development.
• Composite and electronics industries: safety verification for o-CNT-reinforced polymers, conductive adhesives, battery electrodes, and printed electronics intended for consumer contact applications.

FAQ

Why do oxidized carbon nanotubes require toxicity testing separate from pristine CNTs?

Surface oxidation fundamentally changes nanotube behavior in biological systems. Increased carboxyl content typically improves dispersion and reduces length (cutting effect), which can lower inflammatory and fibrotic potential, but greater dispersibility may simultaneously increase cellular uptake and membrane interaction. Because these effects offset each other unpredictably, direct experimental assessment of each specific o-CNT grade is required rather than extrapolation from pristine CNT data.

Do carbon nanotubes interfere with standard toxicity assays?

Yes. CNTs absorb light at wavelengths used in MTT and other colorimetric assays, quench fluorescence, adsorb dyes and proteins, and can physically retain formazan crystals. This is why ISO 19007 exists as a CNT-specific cytotoxicity method, and why laboratories run nanomaterial-only blanks, interference controls, and orthogonal assay confirmation. Reputable testing always includes these controls in the final data interpretation.

What sample quantity is typically required for a full assessment?

In vitro screening packages generally require 100–500 mg of dry powder or equivalent dispersion. Acute in vivo studies may require several grams depending on dose levels and study design, while sub-chronic inhalation studies can require tens of grams. Samples should be accompanied by a certificate of analysis documenting purity, functional group content, and residual catalyst metals.

How long does a biotoxicity assessment take?

In vitro cytotoxicity, oxidative stress, and hemocompatibility panels are typically completed within 3–6 weeks including dispersion characterization. Genotoxicity batteries require approximately 6–10 weeks. Acute in vivo studies take 4–8 weeks, and sub-chronic 90-day studies including recovery periods require 4–6 months. Turnaround also depends on scheduling at accredited third-party laboratories.

Which standards are most commonly referenced in test reports?

Core references include ISO 10993 series (especially parts 3, 4, 5, 10, 11, and 12), ISO/TR 10993-22 for nanomaterials, ISO 19007 for CNT cytotoxicity, ISO 29701 for endotoxin, ISO 10808 for inhalation toxicology, OECD technical guidelines 403, 423, 425, 429, 471, 487, and 489, ASTM E2524, E2525, and E2526, and GB/T 16886 series for submissions in the Chinese market.

What results indicate acceptable biological safety?

Typical acceptance benchmarks include cell viability above 70% relative to negative control at intended-use concentrations (ISO 10993-5), hemolysis rates below 5%, absence of genotoxicity signals in two or more assay endpoints, negative sensitization and irritation findings, and no adverse effects at exposure margins relevant to the intended application. Final conclusions must integrate dose, exposure route, and material characterization data rather than relying on any single endpoint.